



EUROPEAN UNION OF MEDICAL SPECIALISTS
The European Accreditation Council for
Continuing Medical Education – EACCME®
 Institution of the UEMS_{aisbl}

AVENUE DE LA COURONNE, 20
 BE- 1050 BRUSSELS
www.eaccme.eu

T +32 2 649 51 64
 F +32 2 640 37 30
accreditation@uems.net

Conflict of Interest Disclosure Form

(to be completed by scientific/organising committee members)

NAME: *Ashutosh Tewari*
 AFFILIATION: *Icahn School of Medicine at Mount Sinai*

In accordance with criterion 24 of document UEMS 2012/30 "Accreditation of Live Educational Events by the EACCME", all declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations also must be made readily available, either in printed form, with the programme of the LEE, or on the website of the organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement for reimbursement of expenses in relation to the LEE has been provided.

DISCLOSURE

- I have no potential conflict of interest to report
 I have the following potential conflict(s) of interest to report

Please see enclosed Statement

Type of affiliation / financial interest

Name of commercial company

Receipt of grants/research supports:

Please reference attached slide.

Receipt of honoraria or consultation fees:

Prudential / PGIM: Speakers ENGAGEMENT: \$10,000 - 11/15/19

Participation in a company sponsored speaker's bureau:

NA.

Stock shareholder:

PROMAXO - details attached

Spouse/partner:

MAMTA TEWARI

Other support (please specify):

Signature:

Date:

3/21/19

COMPANY	RELATIONSHIP TYPE	FINANCIAL
Novartis	Scientific Study or Trial	Yes
Boston Scientific Corporation	Sponsored Research	No
Novartis Foundation	Donation	Yes
Novartis Foundation	Donation	Yes
DBP Asian Biotech, Vantage Orthopedic and Surgical Promoters - ID# 100909	Patent	No
Global Prostate Cancer Research Foundation	Leadership Position	No
High Intensity Focus Ultrasound and GPS-Biobinary SIRNA for Treatment of Prostate Cancer - ID# 100103	Patent	No
Intuitive Surgical	Scientific Study or Trial	Yes
Hahnemann Cancer Institute	Leadership Position	No
Webb Jones - (8/15/2013)	Sponsored Research	No
Altera (Grant #)	Funding	Yes
Patent for a Gallbladder, Duode and Appendix	Patent	No
Peter Greenberg Foundation Award	Leadership Position	Yes
Peter Kellaway Foundation	Donation	Yes
Postgraduate Institute for Medicine	Teaching/Lectures	No
Promaxo	Leadership Position	Yes
Tremaxo	Equity Ownership	YES
Prostate Cancer Foundation	Leadership Position	No
Rehab	Consultant	No
Stamps	Advisory	Yes
Tim O'Neill Foundation	Donation	Yes
Urbair, Schmeckels, Radical Prostatectomy	Patent	No

*PROMAXO: Common Stock Certificate VALUE: 51,205
 % SHARE RELATED PARTY: 0.63

-Intuitive -- no salary/ see referenced COI's
 -Promaxo - no salary/investment -- see referenced COI's
 -Kite Pharma: Serve as PI. Industry funded for research procedures. Site PI performance -- no salary
 -Poly ICLC : Serve as site PI. Phase I Study of IN SITU Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic HILTONOL (POLY-ICLC) Prior to Radical Prostatectomy. Product provided free of charge -- no other funding. No salary

*Dr. Ash Tewari (the Principal Investigator in this study and Chairman of Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai) owns equity in the form of stock certificates in Promaxo, for which he serves as an advisor. Promaxo is a privately traded company which develops MRI technology with a focus on prostate cancer.